18 results about "Microvascular endothelium" patented technology

The invention discloses a construction method of a coronary artery microcirculation disturbance cell model, and belongs to the technical field of biological medicine. According to the method, mouse heart microvascular endothelial cells (MCMEC) are taken as objects, tetrachlorohydroquinone (TCHQ) is used for treating for 6 hours at the concentration of 20-40 [mu] M, and CMD typical characteristics such as apoptosis, increase of reactive oxygen species (ROS), reduction of nitric oxide (NO) and release of inflammatory factors (TNF-alpha and IL-1beta) of the cells are induced. The TCHQ is applied to construction of the CMD model for the first time, and the model is stable, good in repeatability and capable of being used for CMD pathogenesis research and drug screening.

The application provides an application of scEMC10 in treatment and diagnosis of brain vascular endothelial cell aging, and relates to the technical field of biomedicine. The inventor finds that scEMC10 deficiency leads to brain microvascular endothelial cell aging; brain microvascular endothelial cells treated by scEMC10 can down-regulate beta-galactosidase, SASP and classic aging markers related to aging; after old mice and 5XFAD model mice of Alzheimer's disease are supplemented with scEmc10, the movement coordination ability and spatial cognitive ability of the mice can be obviously improved, and the relative content of the Parkinson's disease marker, phosphorylated alpha-synuclein, of the old mice can be obviously reduced, and the content of the tyrosine hydroxylase phosphorylation activity form can be increased. Therefore, scEMC10 can be used for treatment of brain microvascular endothelial cell aging, improvement of Alzheimer's disease and Parkinson's disease, and detection of brain microvascular endothelial cell aging as a marker.

The present application relates to the technical field of nano-preparation, in particular to an extracellular vesicle-liposome hybrid nanoparticle and a preparation method and application thereof. The extracellular vesicle-liposome hybrid nanoparticle provided by the present application significantly improves the ability of drugs to cross the blood-brain barrier and the target enrichment efficiency of ischemic lesions in the brain through active targeting modification; the specific response release of drugs is realized by using the high active oxygen microenvironment of the lesion, non-specific distribution of drugs is reduced, and the systemic toxic side effects are reduced; ultimately, a multi-target point synergistic treatment system capable of synchronously regulating neural cell apoptosis, glial cell inflammatory activation, brain microvascular endothelial cell ferroptosis and the structural integrity of the blood-brain barrier is constructed, the problem that the effect of traditional single target point intervention is limited is broken through from the root, and a more efficient, safe and precise new treatment strategy is provided for cerebral ischemia-reperfusion injury.

The application relates to the technical field of medicines, and particularly discloses a polypeptide and application of the polypeptide in preparation of a medicine for ischemic stroke. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide can significantly improve the nerve function defect of a mouse transient middle cerebral artery occlusion / reperfusion (tMCAO / R) model in vivo, reduce the cerebral infarction volume, and reduce the whole-body oxidative stress level. In vitro, the polypeptide has a direct protective effect on HT22 cells of mouse hippocampal neurons and hCMEC / D3 cells of human brain microvascular endothelium induced by oxygen-glucose deprivation (OGD), can resist the damage of corticosterone and MPP + induced PC12 cells, and effectively inhibits the accumulation of reactive oxygen species (ROS) in cells. The results show that the polypeptide has a multi-target cell protection activity, can play an anti-ischemic stroke role from multiple dimensions such as reduction of infarction volume, inhibition of oxidative stress level, and protection of nerve vascular units.

The invention belongs to the technical field of disease treatment, and particularly relates to a composition for regulating blood sugar and microvascular homeostasis and a preparation method thereof. The composition for regulating the blood sugar and the microvascular homeostasis is prepared from the following components in parts by mass: 380 to 520 parts of peony seed oil, 260 to 440 parts of dihydromyricetin and 0.025 to 0.062 part of chromium picolinate. The composition for regulating blood sugar and microvascular homeostasis can be used for protecting microvessels, regulating blood sugar, improving microcirculation of the whole body and preventing diabetic complications, and is suitable for preventing and treating diseases such as hyperglycemia, hyperlipidemia and glycolipid metabolism syndrome. Experiments on vascular endothelial dysfunction of obese rats show that the composition disclosed by the invention can be used for remarkably improving microvascular endothelial functions of the obese rats and effectively delaying rise of arterial blood pressure. Experiments on mouse diabetic cardiomyopathy find that the composition has a definite myocardial protection effect on DCM mice.

The invention belongs to the technical field of molecular biology, and discloses application of DDX24 in maintaining the homeostasis of an intestinal vascular barrier. According to the present invention, the low expression of the intestinal microvascular endothelial DDX24 in the inflammatory bowel disease (IBD) is firstly found so as to construct the adult endothelial cell specific DDX24 induced knockout mouse model, the homeostasis of the intestinal vascular barrier (GVB) of the mouse is imbalanced, and the mouse suffers from spontaneous enteritis, such that the intestinal microvascular endothelial cell DDX24 is the important molecule for maintaining the intestinal homeostasis; and mechanism research finds that the intestinal microvascular endothelial cell DDX24 inhibits cell senescence to protect the GVB steady state. The research discloses an important mechanism of DDX24 for protecting GVB homeostasis by inhibiting intestinal microvascular endothelial cell senescence for the first time, and provides a strategy and basis for clinical diagnosis and treatment of IBD vascular barrier.

This invention belongs to the field of organ-on-a-chip technology, providing a blood-brain barrier / neuronal co-culture chip, an organ-on-a-chip, its construction method, and applications. The blood-brain barrier / neuronal co-culture chip provided by this invention includes a reservoir, vascular endothelial channels, a hydrogel chamber, and a brain region microenvironment channel. The vascular endothelial channels are used for seeding brain microvascular endothelial cells; the hydrogel chamber is used for seeding brain perivascular cells and astrocytes, and exchanges substances with the vascular endothelial channels through a porous membrane; the brain region microenvironment channel is used for seeding neurons, constructing a three-dimensional neuronal network growth environment. Using this blood-brain barrier / neuronal co-culture chip as the chip body, the construction of the blood-brain barrier, the glial support microenvironment, and the three-dimensional developmental space of neurons can be realized, achieving dynamic interaction between the blood-brain barrier and the neuronal microenvironment. It has broad application prospects in the study of the mechanisms of nervous system diseases and the evaluation of nervous system drugs.

This invention discloses an siRNA that slows down endothelial-mesenchymal transition (EMT) and a cell line with low GTF2H4 expression. The invention provides three siRNAs that knock down GTF2H4 expression using RNAi, with sequences shown in SEQ ID NO: 1-6. It also provides shRNAs with sequences shown in SEQ ID NO: 13-14, and constructs a microvascular endothelial cell line with low GTF2H4 expression based on these sequences. This cell line significantly inhibits hypoxia-induced EMT, suppresses cell migration, and promotes cell tube formation. This provides new hope for clinical intervention in EMT to improve cardiovascular disease and facilitates further research to explore the potential molecular mechanisms between GTF2H4 and EMT, offering useful clues for treating cardiovascular diseases caused by EMT and possessing significant application value.

The invention relates to the technical field of cell sensing, and discloses a brain microvascular endothelial cell injury assessment method, which comprises the following steps of: synchronously acquiring a metabolic vibration signal and a transcellular resistance signal of brain microvascular tissues through a sensor carrier integrating a piezoelectric sensing unit and an electrode unit, and calculating a correlation coefficient of time domain envelope of the signals; the cell damage state is judged based on continuous negative correlation, early warning of cell function instability is achieved through double-signal dynamic coupling analysis, a harmonic phase locking recognition mechanism can capture the recessive pathological state in the compensation period, and signal entropy change compensation enables the system to have the capacity of self-adaption to environment interference. And a real-time and accurate capillary function evaluation means is provided for clinic.

Provided is a technology allowing for stable supply of brain microvascular endothelium-like cells. This coating agent for inducing differentiation of pluripotent stem cells into brain microvascular endothelium-like cells contains at least one component of a Laminin-221 fragment or an N-terminal Vitronectin.

Provided is a fluidic chip, comprising: a bottom region, the bottom region comprising a central channel and at least one side channel adjacent thereto, the central channel having therein a plurality of cells disposed in a matrix; and a middle region, the middle region having a chamber defined therein, the chamber optionally being an open-top chamber, the chamber being in register with at least one of the central channel and the at least one side channel of the bottom region. Also provided is a method, comprising co-culturing airway epithelial cells, pulmonary microvascular endothelial cells, and lung fibroblasts using a fluidic chip; the airway epithelial cells comprising airway cells or alveolar cells. Also disclosed is causing contact between (1) at least one of an agent and a stimulus, and (2) epithelial cells disposed within the chamber of a fluidic chip, and monitoring at least one marker indicative of exposure of the epithelial cells to the sample.

The invention discloses a co-culture solution, a construction method of an in-vitro organ-like model, the in-vitro organ-like model and application of the in-vitro organ-like model, and belongs to the technical field of biological medicine. The DMEM culture medium contains 4-hydroxyethylpiperazine ethanesulfonic acid, L-alanyl-L-glutamine, an N2-additive, a G-5 additive, a B-27 additive, a human epidermal growth factor, penicillin-streptomycin and fetal calf serum, and the MCEB131 culture medium is used for culturing the human epidermal growth factor, the penicillin-streptomycin and the fetal calf serum. The co-culture solution provided by the invention can realize co-culture of human astrocytes SVGP12, human microvascular endothelial cells HMEC-1 and human perineuronal cells HBVP, avoids the interference of cross components of different nutrient solutions on the cells, and improves the stability of an in-vitro organ-like model.

The invention discloses a targeting microbubble for targeting microvascular endothelium as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The targeted microvesicle of the targeted microvascular endothelium provided by the invention comprises a biotinylated liposome microvesicle combined with streptavidin and a biotinylated carbonic anhydrase 4 antibody, the biotinylated liposome microbubble combined with streptavidin takes lipid as a shell membrane material, fluorinated inert gas is wrapped in the shell membrane material, and the surface of the shell membrane material is combined with streptavidin; and the shell membrane material is prepared from DSPC (Distearoyl Pyrrolidone), DSPE-PEG (Polyethylene Glycol) 2000 and DSPE-PEG 2000-biotin. The targeting microbubble has good targeting property, biocompatibility and safety, and can intuitively reflect the density difference of microvessels, thereby providing an intuitive and reliable imaging basis for early diagnosis and disease assessment of coronary artery microvascular diseases.

The invention discloses an application of an exosome carrying miR-125a-5p in acute lung injury, and belongs to the technical field of biological medicines. The invention proposes that the miR-125a-5p and the human umbilical cord mesenchymal stem cell source carrying the miR-125a-5p exosome can be used for treating the acute lung injury for the first time; the miR-125a-5p and the human umbilical cord mesenchymal stem cell source carrying the miR-125a-5p exosome can improve the development process of the mouse acute lung injury by means of reducing lung microvascular endothelial cell ferroptosis, reducing expression of intercellular adhesion molecules and improving lung inflammation, and a new thought is provided for the pathogenesis of the acute lung injury. The research on related mechanisms of occurrence and development of the acute lung injury is further perfected. According to the invention, a theoretical basis and related experimental data support can be provided for clinical early diagnosis, early treatment and future development of targeted miRNA drugs and treatment of acute lung injury.

Described herein is a biocompatible lipid nanoparticle (LNP) composition suitable for delivering RNA payloads into cells and tissues of a subject. The biocompatible LNPs comprise an ionizable cationic lipid as a core component and have a net neutral surface charge at physiological pH. Delivery of LNP-encapsulated siRNA inhibiting the expression Spermidine / spermine N1-acetyltransferase 1 (SAT1) is shown to inhibit proliferation of a glioblastoma cell line, but not in other cells pertinent to brain tissue such as microvascular endothelial cells, primary human astrocytes, and macrophage cells. Use of a cadherin-binding peptide to increase delivery of LNP-encapsulated siRNA across a blood-brain barrier monolayer model is also described.

The invention belongs to the technical field of cell culture, and particularly relates to a microvascular endothelial cell culture method and application thereof. A culture solution used in the culture method comprises a basic culture medium, fetal calf serum, HEPES, Glutamax, N2, G-5, B-27, hEGF and antibiotics, wherein the basic culture medium is formed by mixing DMEM (Dulbecco Modified Eagle Medium) and MCDB 131 in a ratio of 1: 1. According to the culture solution, by optimizing the components and the proportion thereof, the in-vitro proliferation rate of HMEC-1 cells can be remarkably promoted, and the high-activity state and normal functional characteristics of the cells in the long-term culture process are effectively maintained; the technical problems that the cell proliferation efficiency is low and the cell activity and function are difficult to maintain in a long-term culture state in an existing culture method are solved. The culture system provided by the invention is clear in component and simple and convenient to operate, and a stable and reliable technical platform is provided for related research of the microvascular endothelial cells.

According to the application of the methylated transferase G9a / GLP specific inhibitor in preparing the medicine for treating the fundus neovascularization diseases, based on an epigenetics regulation and control mechanism, it is found that the histone methylated transferase G9a / GLP specific inhibitor can be used for preparing the medicine for treating the fundus neovascularization diseases by inhibiting proliferation, migration and angiogenesis capacity of retina microvascular endothelial cells; the composition can effectively block formation and abnormal leakage of fundus neovascularization in vivo and in vitro, is good in safety, is applied to treatment of fundus neovascularization diseases for the first time, breaks through action limitation of traditional treatment, and has good application prospects. The technical problems of large administration trauma, poor compliance, single action mechanism, high drug resistance risk, incapability of radical treatment, heavy economic burden and the like in the existing fundus neovascularization treatment technology are solved, and a novel treatment scheme which is wide in action target spot, good in safety, convenient in administration, controllable in cost and capable of regulating and controlling the pathological process from the upstream is provided. The application blank of the epigenetic inhibitor in the field of ophthalmology neovascularization treatment is filled.

This invention discloses a brain delivery nanocarrier via a transcellular transport pathway. It uses a lecithin-modified inorganic nanomaterial as its core and a membrane-fused liposome-cell membrane as its shell. The membrane-fused liposome-cell membrane coats the surface of the lecithin-modified inorganic nanomaterial, forming a core-shell structure. The membrane-fused liposome-cell membrane is formed by the hybridization and fusion of membrane-fused liposomes with the cell membranes of metastatic brain cancer cells. This brain delivery nanocarrier can efficiently cross the blood-brain barrier via a membrane fusion pathway, bypassing the classic endocytosis-lysosome pathway to enter brain microvascular endothelial cells, thus solving the problems of low delivery efficiency and easy retention and degradation in lysosomes of existing nanomaterials.